Takuya Iyoda
Overview
Explore the profile of Takuya Iyoda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Otsuka K, Sasada M, Iyoda T, Nohara Y, Sakai S, Asayama T, et al.
Am J Cancer Res
. 2020 Feb;
10(1):365-366.
PMID: 32064173
[This corrects the article on p. 434 in vol. 9, PMID: 30906641.].
12.
Sasada M, Iyoda T, Asayama T, Suenaga Y, Sakai S, Kase N, et al.
Oncotarget
. 2019 Aug;
10(48):4960-4972.
PMID: 31452837
The family oncogenes (, , and ) contribute to the genesis of many human cancers. Among them, amplification of the gene and over-expression of N-Myc protein are the most reliable...
13.
Otsuka K, Sasada M, Hirano Y, Nohara Y, Iyoda T, Higami Y, et al.
Anticancer Res
. 2019 Jul;
39(7):3487-3492.
PMID: 31262872
Background/aim: Despite intensive chemotherapy, the survival rates for high-risk neuroblastoma, most of which have MYCN amplification, remain low. Overexpression of N-myc oncoprotein promotes expression of cancer-associated properties. We recently found...
14.
Fujita M, Yamamoto T, Iyoda T, Fujisawa T, Nagai R, Kudo C, et al.
Int J Mol Sci
. 2019 Jul;
20(13).
PMID: 31261783
Expression level of tenascin-C is closely correlated to poor prognosis in glioblastoma patients, while the substantial role of tenascin-C responsible for aggressive progression in glioblastoma cells has not been clarified....
15.
Fujita M, Ito-Fujita Y, Iyoda T, Sasada M, Okada Y, Ishibashi K, et al.
Int J Mol Sci
. 2019 Jun;
20(11).
PMID: 31195598
Inflammatory bowel diseases increase the risk of colorectal cancer and colitis-associated colorectal cancer (CAC). Tenascin-C, a matricellular protein, is highly expressed in inflammatory bowel diseases, especially colorectal cancer. However, the...
16.
Fujita M, Yamamoto T, Iyoda T, Fujisawa T, Sasada M, Nagai R, et al.
Mol Cancer Ther
. 2019 Jun;
18(9):1649-1658.
PMID: 31189613
Tenascin-C is a member of the matricellular protein family, and its expression level is correlated to poor prognosis in cancer, including glioblastoma, whereas its substantial role in tumor formation and...
17.
Otsuka K, Sasada M, Iyoda T, Nohara Y, Sakai S, Asayama T, et al.
Am J Cancer Res
. 2019 Mar;
9(2):434-448.
PMID: 30906641
Neuroblastoma is one of the common solid tumors of childhood. Nearly half of neuroblastoma patients are classified into the high-risk group, and their 5-year event-free survival (EFS) rates remain unsatisfactory...
18.
Iijima K, Tsuji Y, Kuriki I, Kakimoto A, Nikaido Y, Ninomiya R, et al.
Colloids Surf B Biointerfaces
. 2017 Sep;
160:228-237.
PMID: 28942157
We have developed polysaccharide composite films made of anionic polysaccharides and chitosan (CHI) by utilizing hot press techniques. In order to demonstrate the versatility of these films as cell scaffolds,...
19.
Suzuki H, Sasada M, Kamiya S, Ito Y, Watanabe H, Okada Y, et al.
Int J Mol Sci
. 2017 Jan;
18(1).
PMID: 28106752
The extracellular matrix (ECM) molecule tenascin C (TNC) is known to be highly expressed under various pathological conditions such as inflammation and cancer. It has been reported that the expression...
20.
Iyoda T, Nagamine Y, Nakane Y, Tokita Y, Akari S, Otsuka K, et al.
PLoS One
. 2016 Sep;
11(9):e0162525.
PMID: 27622612
The acquisition of drug resistance mediated by the interaction of tumor cells with the extracellular matrix (ECM), commonly referred to as cell adhesion-mediated drug resistance (CAM-DR), has been observed not...